AAN 2022

Effects of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, on Slowly Expanding Lesions, an Emerging Imaging Marker of Chronic Tissue Loss in Multiple Sclerosis

Arnold | Oral #S14.009

Safety Profile Characterization of Evobrutinib in Over 1000 Patients from phase 2 Clinical Trials in Multiple Sclerosis, Rheumatoid Arthritis and Systemic Lupus Erythematosus

Guehring | Oral #S14.007

The Role of Human and Mouse BTK in Myeloid Cells

Bassani | Poster #3.4-006

Comparative Effectiveness of Cladribine Versus Fingolimod in the Treatment of Highly Active Relapsing Multiple Sclerosis: The MERLYN Study

Brownlee | Poster #7.4-005

Real-World Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry

Butzkueven | Poster #12.4-003

Exploratory Analysis of Serum GDF-15 Levels in Patients Receiving Subcutaneous Interferon β-1a in the REFLEX Trial

Coray | Poster #2.4-007

Post-approval Safety of Subcutaneous Interferon β-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections

Freedman | Poster #8.4-005

Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis or Active Secondary Progressive Multiple Sclerosis After Suboptimal Response to a Disease-Modifying Therapy (CLICK-MS and MASTER-2): Interim Baseline and Safety Review

Miravalle | Poster #1.296

Safety and Efficacy of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor in Relapsing Multiple Sclerosis over 2.5 Years of the Open-Label Extension to a phase 2 Trial

Montalban | Poster #5.4-001

Patient Practices and Experiences During COVID-19 Among Individuals Across the United States Enrolled in MS LifeLines Patient Support Program

Nicholas | Poster #1.338

A Cross-Sectional Survey Evaluating Cladribine Tablets Treatment Patterns Among Patients with Multiple Sclerosis Across the US Enrolled in the MS LifeLines Patient Support Program

Nicholas | Poster #1.340

INFORM - Interferon Beta Exposure in the 2nd and 3rd Trimester of Pregnancy - A Register-Based Drug Utilisation Study in Finland and Sweden

Sabidó | Poster #8.4-009

Clinical Outcomes in Patients with COVID-19 During Two Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis: An Update

Yavorskaya | Poster #11.4-005